EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia ,

ISSN 2394-3211

Impact Factor: 7.065

ICV - 79.57

Abstract

INCIDENCE OF ANTIVIRAL THERAPY IN AMELIORATING HEPATITIS C ASSOCIATED COMORBIDITIES IN TAIWAN: A 7 YEAR FOLLOW UP NATIONWIDE POPULATION-BASED STUDY

Yueh-Chin Chung, Ph. D., Shu-Fen Li, Ph. D., Mei-Wen Lee, Ph. D., Chien-Wei Wu, MBA., Horng-Mo Lee, Ph. D., Chin-Chih Ho, Ph. D. and Chin-Tun Hung, Ph. D.*

ABSTRACT

Objectives: Hepatic C Virus (HCV) infection is associated with development of type 2 diabetes (T2D). This population-based study was designed to assess whether anti-viral therapy following HCV-infected hepatitis may reduce the incidence rates of T2D and hazard ratios for associated cormobidities. Methods: A total of 13,025 subjects were retrieved from the NHIRD cohort from 2000 to 2003. Among them, 2641 (20%) were diagnosed with HCV-infected hepatitis, and 10,564 HCV negative subjects served as control group. Among the 2,641 HCV-infected subjects, 139 (5.3%) subjects received IFN/RBV therapy.The other 2,502 hepatitis C patients not receiving IFN/RBV therapy served as comparison group. Results: Among the 10,564 HCV sero-negative control subjects, 920 subjects (8.7%) developed T2D in 7 years. On the other hand, there were 444 (16.8%) HCV-infected subjects developed T2D in 7 years. HCV-hepatitis patients were more likely to develop T2D (hazard ratio 2.097, 95% CI 1.872–2.348; p <0.001). Among the 2502 HCV patients not receiving IBT therapy, 434 patients (17.3%) developed T2D in 7 years. In contrast, only 10 (7.2%) in 139 HCV-infected subjects who received IBT therapy developed T2D in 7 years. The adjusted hazard ratio was 0.341 (95% CI 0.182–0.639; p<0.001).The hepatitis C patients have a higher incidence of T2D, hepatic steatosis, cardiovascular disorders and hepatocellular carcinoma (HCC). After interferon-base therapy intervention T2D significantly reduce its incidence. Conclusions: Our data suggest that HCV infection was associated with increased risk of T2D, and anti-viral therapy may be reduce the incidence of T2D.

Keywords: Hepatitis C virus (HCV), Type 2 diabetes (T2D), Epidemiology, Incidence, Hazard ratios.

[Full Text Article] [Download Certificate]